OpenURL Connection Search

Select item for more details and to access through your institution.

Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Published in:
British Journal of Haematology, 2015, v. 169, n. 2, p. 188, doi. 10.1111/bjh.13273
By:
- Purroy, Noelia;
- Bergua, Juan;
- Gallur, Laura;
- Prieto, Julio;
- Lopez, Luis A.;
- Sancho, Juan M.;
- García‐Marco, Jose A.;
- Castellví, Josep;
- Montes‐Moreno, Santiago;
- Batlle, Ana;
- Villambrosia, Sonia Gonzalez;
- Carnicero, Fernando;
- Ferrando‐Lamana, Lucía;
- Piris, Miguel A;
- Lopez, Andrés
Publication type:
Article
Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
Published in:
2018
By:
- Montoro, Julia;
- Gallur, Laura;
- Merchán, Brayan;
- Molero, Antonieta;
- Roldán, Elisa;
- Martínez-Valle, Ferrán;
- Villacampa, Guillermo;
- Navarrete, Mayda;
- Ortega, Margarita;
- Castellví, Josep;
- Saumell, Silvia;
- Bobillo, Sabela;
- Bosch, Francesc;
- Valcárcel, David
Publication type:
journal article
Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
Published in:
Annals of Hematology, 2010, v. 89, n. 11, p. 1073, doi. 10.1007/s00277-010-0997-y
By:
- Peñalver, Francisco Javier;
- Alvarez-Larrán, Alberto;
- Díez-Martin, Jose;
- Gallur, Laura;
- Jarque, Isidro;
- Caballero, Dolores;
- Díaz-Mediavilla, Joaquín;
- Bustelos, Rosalía;
- Fernández-Aceñero, María;
- Cabrera, José
Publication type:
Article
Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
Published in:
Annals of Hematology, 2006, v. 85, n. 6, p. 400, doi. 10.1007/s00277-005-0073-1
By:
- Peñalver, Francisco;
- Jiménez-Yuste, Victor;
- Almagro, Manuel;
- Alvarez-Larrán, Alberto;
- Rodríguez, Lluis;
- Casado, Marisol;
- Gallur, Laura;
- Giraldo, Pilar;
- Hernández, Roberto;
- Menor, Dolores;
- Rodríguez, Maria;
- Caballero, Dolores;
- González, Raúl;
- Mayans, José;
- Millán, Isabel;
- Cabrera, José
Publication type:
Article

Found: 4

Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.

Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.

Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.

Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.